Top

Published in:

01-02-2021 | Cytostatic Therapy | Original Article

Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial

Authors: Terry Trinh, Susanna B. Park, Jenna Murray, Hannah Pickering, Cindy S.-Y. Lin, Andrew Martin, Michael Friedlander, Matthew C. Kiernan, David Goldstein, Arun V. Krishnan

Published in: Supportive Care in Cancer | Issue 2/2021

Abstract

Trial design

Peripheral neuropathy is a commonly reported adverse effect of oxaliplatin treatment, representing a significant limitation which may require discontinuation of effective therapy. The present study investigated the neuroprotective potential of riluzole in patients undergoing oxaliplatin treatment in a randomised-controlled trial comparing riluzole and placebo-control.

Methods

Fifty-two patients (17 females, 58.1 ± 12.7 years) receiving oxaliplatin treatment were randomised into either a treatment (50 mg riluzole) or lactose placebo group. The primary outcome measure was the total neuropathy score-reduced (TNSr). Secondary outcome measures include nerve excitability measures, 9-hole pegboard and FACT-GOG NTX questionnaire. Patients were assessed at baseline, pre-cycle 10 or 12, 4-week and 12-week post-treatment.

Results

Both the treatment and placebo groups developed objective and patient reported evidence of neurotoxicity over the course of oxaliplatin treatment, although there were no significant differences across any parameters between the two groups. However, across follow-up assessments, the treatment group experienced greater neuropathy, represented by a higher TNSr score at 4-week post-chemotherapy of 8.3 ± 2.7 compared with 4.6 ± 3.6 (p = 0.032) which was sustained at 12-week post-treatment (p = 0.089). Similarly, patients in the treatment group reported worse symptoms with a FACT-GOG NTX score of 37.4 ± 10.2 compared with 43.3 ± 7.4 (p = 0.02) in the placebo group at 4-week post-treatment.

Conclusion

This study is the first to provide an objective clinical investigation of riluzole in oxaliplatin-induced peripheral neuropathy employing both functional and neurophysiological measures. Although the recruitment target was not reached, the results do not show any benefit of riluzole in minimising neuropathy and may suggest that riluzole worsens neuropathy associated with oxaliplatin treatment.

Available only for authorised users

McKeage MJ, Hsu T, Screnci D, Haddad G, Baguley BC (2001) Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85(8):1219–1225. https://doi.org/10.1054/bjoc.2001.2024CrossRefPubMedPubMedCentral

Amptoulach S, Tsavaris N (2011) Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011:843019–843015. https://doi.org/10.1155/2011/843019CrossRefPubMedPubMedCentral

Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29(5 Suppl 15):11–20. https://doi.org/10.1053/sonc.2002.35524CrossRefPubMed

Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, Alberti P, Bergamo F, Cortinovis D, Cazzaniga M, Santos C, Papadimitriou K, Kalofonos HP (2013) Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer 119(2):438–444. https://doi.org/10.1002/cncr.27732CrossRefPubMed

Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772–781. https://doi.org/10.1002/ana.24951CrossRefPubMedPubMedCentral

Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, Frigeni B, Cacciavillani M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Kalofonos HP (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85(4):392–398. https://doi.org/10.1136/jnnp-2013-305334CrossRefPubMed

Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32(1):51–60. https://doi.org/10.1002/mus.20340CrossRefPubMed

Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13–16. https://doi.org/10.1159/000094376CrossRefPubMed

Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG (2004) Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127(Pt 2):294–303. https://doi.org/10.1093/brain/awh032CrossRefPubMed

10.

Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ (2003) Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53(2):174–180. https://doi.org/10.1002/ana.10443CrossRefPubMed

11.

Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406(1):25–32. https://doi.org/10.1016/s0014-2999(00)00667-1CrossRefPubMed

12.

Deuis JR, Zimmermann K, Romanovsky AA, Possani LD, Cabot PJ, Lewis RJ, Vetter I (2013) An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. Pain 154(9):1749–1757. https://doi.org/10.1016/j.pain.2013.05.032CrossRefPubMedPubMedCentral

13.

Sittl R, Lampert A, Huth T, Schuy ET, Link AS, Fleckenstein J, Alzheimer C, Grafe P, Carr RW (2012) Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A 109(17):6704–6709. https://doi.org/10.1073/pnas.1118058109CrossRefPubMedPubMedCentral

14.

Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15(29):3081–3094. https://doi.org/10.2174/092986708786848569CrossRefPubMed

15.

Heide R, Bostock H, Ventzel L, Grafe P, Bergmans J, Fuglsang-Frederiksen A, Finnerup NB, Tankisi H (2018) Axonal excitability changes and acute symptoms of oxaliplatin treatment: in vivo evidence for slowed sodium channel inactivation. Clin Neurophysiol 129(3):694–706. https://doi.org/10.1016/j.clinph.2017.11.015CrossRefPubMed

16.

Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24(12):5059–5068. https://doi.org/10.1007/s00520-016-3373-1CrossRefPubMedPubMedCentral

17.

Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132(Pt 10):2712–2723. https://doi.org/10.1093/brain/awp219CrossRefPubMed

18.

Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996). Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 (9013):1425–1431. doi:https://doi.org/10.1016/s0140-6736(96)91680-3

19.

Cheah BC, Vucic S, Krishnan AV, Kiernan MC (2010) Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 17(18):1942–1199. https://doi.org/10.2174/092986710791163939CrossRefPubMed

20.

Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17(1):4–31. https://doi.org/10.1111/j.1755-5949.2009.00116.xCrossRefPubMedPubMedCentral

21.

Leinster VH, Robson LG, Shortland PJ (2010) Differential effects of riluzole on subpopulations of adult rat dorsal root ganglion neurons in vitro. Neuroscience 166(3):942–951. https://doi.org/10.1016/j.neuroscience.2009.12.058CrossRefPubMed

22.

Yamamoto S, Egashira N, Tsuda M, Masuda S (2018) Riluzole prevents oxaliplatin-induced cold allodynia via inhibition of overexpression of transient receptor potential melastatin 8 in rats. J Pharmacol Sci 138(3):214–217. https://doi.org/10.1016/j.jphs.2018.10.006CrossRefPubMed

23.

Yamamoto S, Ushio S, Egashira N, Kawashiri T, Mitsuyasu S, Higuchi H, Ozawa N, Masuguchi K, Ono Y, Masuda S (2017) Excessive spinal glutamate transmission is involved in oxaliplatin-induced mechanical allodynia: a possibility for riluzole as a prophylactic drug. Sci Rep 7(1):9661. https://doi.org/10.1038/s41598-017-08891-1CrossRefPubMedPubMedCentral

24.

Poupon L, Lamoine S, Pereira V, Barriere DA, Lolignier S, Giraudet F, Aissouni Y, Meleine M, Prival L, Richard D, Kerckhove N, Authier N, Balayssac D, Eschalier A, Lazdunski M, Busserolles J (2018) Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology 140:43–61. https://doi.org/10.1016/j.neuropharm.2018.07.026CrossRefPubMed

25.

Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G (2006) Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11(2):135–141. https://doi.org/10.1111/j.1085-9489.2006.00078.xCrossRefPubMed

26.

Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999) Total neuropathy score: validation and reliability study. Neurology 53(8):1660–1664. https://doi.org/10.1212/wnl.53.8.1660CrossRefPubMed

27.

Burke D, Skuse NF, Lethlean AK (1974) Sensory conduction of the sural nerve in polyneuropathy. J Neurol Neurosurg Psychiatry 37(6):647–652. https://doi.org/10.1136/jnnp.37.6.647CrossRefPubMedPubMedCentral

28.

Buschbacher RM (1999) Tibial nerve motor conduction to the abductor hallucis. Am J Phys Med Rehabil 78(6 Suppl):S15–S20. https://doi.org/10.1097/00002060-199911001-00004CrossRefPubMed

29.

Krishnan AV, Lin CS, Park SB, Kiernan MC (2009) Axonal ion channels from bench to bedside: a translational neuroscience perspective. 89 (3):288-313. https://doi.org/10.1016/j.pneurobio.2009.08.002

30.

Kiernan MC, Lin CS, Andersen KV, Murray NM, Bostock H (2001) Clinical evaluation of excitability measures in sensory nerve. Muscle Nerve 24(7):883–892. https://doi.org/10.1002/mus.1085CrossRefPubMed

31.

Bostock H, Cikurel K, Burke D (1998) Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 21(2):137–158. https://doi.org/10.1002/(sici)1097-4598(199802)21:2<137::aid-mus1>3.0.co;2-cCrossRefPubMed

32.

Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003). Psychometric evaluation of the functional assessment of cancer therapy/gynecologic oncology group-neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13 (6):741–748. doi:https://doi.org/10.1111/j.1525-1438.2003.13603.x

33.

Argyriou A, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos M, Gourzis P, Assimakopoulos K, Kalofonos HJN (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. 67 (12):2253-2255. https://doi.org/10.1212/01.wnl.0000249344.99671.d4

34.

Vucic S, Lin CS, Cheah BC, Murray J, Menon P, Krishnan AV, Kiernan MC (2013) Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 136(Pt 5):1361–1370. https://doi.org/10.1093/brain/awt085CrossRefPubMed

35.

Lazarevic V, Yang Y, Ivanova D, Fejtova A, Svenningsson P (2018) Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool. Neuropharmacology 143:38–48. https://doi.org/10.1016/j.neuropharm.2018.09.021CrossRefPubMed

36.

Huang CS, Song JH, Nagata K, Yeh JZ, Narahashi T (1997) Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons. J Pharmacol Exp Ther 282(3):1280–1290PubMed

37.

Hebert T, Drapeau P, Pradier L, Dunn RJ (1994) Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol 45(5):1055–1060PubMed

38.

Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67(12):2253–2255. https://doi.org/10.1212/01.wnl.0000249344.99671.d4CrossRefPubMed

39.

Ichikawa K, Koyama N, Kiguchi S, Kojima M, Yokota T (2001) Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibers. Eur J Pharmacol 420(2–3):119–122. https://doi.org/10.1016/s0014-2999(01)01007-xCrossRefPubMed

40.

Schmidt D, Elger CE (2004) What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 5(5):627–635. https://doi.org/10.1016/j.yebeh.2004.07.004CrossRefPubMed

41.

von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, Obermeier F, Erdmann J, Schmelz R, Quasthoff S, Adelsberger H, Bredenkamp R, Schmid RM, Lersch C (2007) Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Investig New Drugs 25(2):173–180. https://doi.org/10.1007/s10637-006-9010-yCrossRef

42.

Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91(9):403–413. https://doi.org/10.1212/WNL.0000000000006083CrossRefPubMedPubMedCentral

43.

Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41(2):161–166. https://doi.org/10.1007/s002800050723CrossRefPubMed

44.

Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL 3rd, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31(20):2627–2633. https://doi.org/10.1200/JCO.2012.44.8738CrossRefPubMedPubMedCentral

45.

Kerckhove N, Busserolles J, Stanbury T, Pereira B, Plence V, Bonnetain F, Krakowski I, Eschalier A, Pezet D, Balayssac D (2019). Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup. BMJ Open 9 (6):e027770. doi:https://doi.org/10.1136/bmjopen-2018-027770

Title: Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial
Authors: Terry Trinh
Susanna B. Park
Jenna Murray
Hannah Pickering
Cindy S.-Y. Lin
Andrew Martin
Michael Friedlander
Matthew C. Kiernan
David Goldstein
Arun V. Krishnan
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keyword: Cytostatic Therapy
Published in: Supportive Care in Cancer / Issue 2/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-020-05591-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Trial design

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Reply to: “Discussing sexuality in cancer care: towards personalized information for cancer patients and survivors”

Simultaneous evaluation of symptoms, swallowing functions, and patient-reported swallowing difficulties and their correlations with ingestion status during definitive chemoradiotherapy for oropharyngeal and hypopharyngeal cancer

Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin

Impact of weight loss on cancer patients’ quality of life at the beginning of the chemotherapy

Effects of preoperative dental examination and oral hygiene instruction on surgical site infection after hepatectomy: a retrospective study

Intensity- and domain-specific physical activity levels between cancer survivors and non-cancer diagnosis individuals: a propensity score matching analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer